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Practice guidelines recommend performing angiography in
arteriovenous fistulae (AVF) when access blood flow (Qa) is
o500 ml/min, but a Qa threshold of o750 ml/min is more
sensitive for stenosis. No economic evaluation has evaluated
the optimal Qa threshold for angiography in AVF, or
determined whether screening AVF is more economically
efficient than intervening only when AVF is thrombosed. We
compared two screening strategies using Qa thresholds of
o750 and o500 ml/min, respectively, with no access
screening. Expected per-patient access-related costs (in 2002
Canadian dollars) were $3910, $5130, and $5250 in the no
screening, QA500, and QA750 arms, respectively over 5 years.
Notably, screening strategies did not reduce expected
access-related costs under any clinically plausible scenario.
The cost to prevent one episode of AVF failure appeared to
be approximately $8000–$10 000 over 5 years for both
screening strategies, compared with no screening. Although
the incremental cost effectiveness of screening (compared to
no screening) was similar in the base case for the QA500 and
QA750 strategies, the relative economic attractiveness of the
QA750 strategy was adversely affected under several
plausible scenarios. Also, the QA750 strategy would require
many additional angiograms to prevent an additional
episode of AVF failure, compared with the QA500 strategy.
Screening of AVF resulted in a modest increase in net costs,
and seems to require a net expenditure of B$9000 to
prevent one episode of AVF failure. If screening is adopted,
our findings suggest that angiography should be performed
when Qa iso500 rather than o750 ml/min, especially when
access to angiography is limited.
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Measurement of access blood flow (Qa) identifies stenosis in
native vessel arteriovenous fistulae (AVF),1 and correction of
stenosis improves access patency.2 Canadian clinical practice
guidelines recommend performing angiography in AVF when
Qa o500 ml/min,3 which is associated with a positive
predictive value for stenosis of approximately 70%. Recent
data suggest that performing angiography when Qa is
o750 ml/min has a higher sensitivity for stenosis without
unduly reducing specificity compared with theo500 ml/min
threshold,2 although this is controversial.1 In addition to the
potential clinical benefits of access flow measurements, a
retrospective study suggests that access blood flow measure-
ments reduce resource use.4
In theory, a higher Qa threshold such as o750 ml/min
might improve patency rates by detecting more AVF with
significant stenoses – allowing them to be preemptively
treated with angioplasty. On the other hand, Qa of
500–750 ml/min are commonly observed in AVF with no
clinical evidence of dysfunction.5 As thrombosis is relatively
infrequent in AVF, and rarely occurs when Qa is 4350 ml/
min,2 a higher Qa threshold might lead to increased resource
use (i.e. angiograms and angioplasties) without improving
access patency. However, a formal economic evaluation has
not been performed to test this hypothesis, or to determine
whether screening AVF for subclinical stenosis is a better use
of scarce resources than reserving intervention for AVF which
have thrombosed.
To assess the economic efficiency of access flow monitor-
ing in AVF, and in an attempt to define the optimal threshold
values for angiography in patients with AVF, we performed
an economic evaluation to examine the costs and con-
sequences of different Qa thresholds for angiography in
patients with native vessel AVF. We compared three strategies:
Qa thresholds for angiography of o750 and o500 ml/min,
respectively, and a comparator arm which involved no access
screening.
RESULTS
Model predictions and face validity
Table 1 shows the outcomes and costs associated with each
strategy over 5 years in the base case scenario. The model
predicted that the proportion of patients who would
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experience an episode of access thrombosis would range from
45.2% in the no screening arm, to 19.6 and 17.1% in the
QA500 and QA750 strategies, respectively. The proportion of
patients predicted to experience fistula loss under each
scenario was 23.4, 9.8, and 8.4%, respectively. By design,
mortality and transplantation rates did not vary between
screening strategies. The model predicted that 81.9% of
patients with untreated stenosis who did not die or receive a
transplant would experience AVF failure over a 5-year period.
The similarity of this prediction to the estimates from the
control arm of a recent randomized trial of patients with AVF
stenosis6 suggests that the model had reasonable validity.
Base case scenario
The expected proportion of patients requiring angiograms
and angioplasties, and the total predicted number of such
procedures were substantially higher under the QA750 and
QA500 strategies, compared with no screening (Table 1). In
addition, the expected proportion of patients who would
require a dialysis catheter, placement of a new AVF, or
placement of a graft were all approximately three times
higher when access screening was not performed compared
with either of the screening arms. Expected per-patient
access-related costs were $3910, $5130, and $5250 in the no
screening, QA500, and QA750 arms, respectively. Notably,
access-screening strategies did not reduce expected access-
related costs under any clinically plausible scenario.
In the base case scenario, the QA500 and QA750 strategies
were associated with superior clinical outcomes and higher
costs compared with the NS strategy. In the base case
analysis, the relative gain in efficacy of the QA750 strategy per
additional dollar spent (compared with the QA500 strategy)
was similar to the relative gain in efficacy of the QA500
strategy (compared with the NS strategy). Thus, in the base
case, the relative economic attractiveness of the two screening
strategies was very similar, although the QA750 strategy was
associated with a higher use of radiological resources.
To offer a more concrete example, consider a hypothetical
dialysis unit which currently treats 100 patients with AVF but
does not perform access screening. Our model predicts that if
such a facility were to adopt the QA500 strategy, additional
costs of $122 000 would result over 5 years. The expected
number needed to screen to prevent one episode of access
failure was 7.4, meaning that the hypothetical dialysis unit
would be expected to observe 13.5 fewer episodes of fistula
loss under the QA500 strategy (vs no screening), and avert the
placement of 43 hemodialysis catheters over 5 years.
In comparison, for a hypothetical dialysis unit of 100
patients, which was performing screening using the QA500
strategy, the model predicted that adopting the QA750
strategy instead would result in 28 additional angiograms,
avert the placement of two hemodialysis catheters, and result
in 1.4 fewer episodes of fistula loss –while increasing net costs
by approximately $12 000 over 5 years.
Sensitivity analyses
In most of the sensitivity analyses, the QA500 strategy
appeared slightly more attractive than the QA750 strategy. In
some scenarios, the QA500 strategy was eliminated by
extended dominance (see Materials and Methods section).
In all such cases, the absolute difference between the QA500
and QA700 strategies was very small, suggesting that either
strategy might be appropriate. However, there were several
scenarios in which the QA500 strategy was substantially more
attractive than the QA750 strategy. For example, a scenario in
which screening was less sensitive and specific for stenosis
(i.e. consistent with the only other prospective study that
subjected all patients undergoing access flow monitoring to
Table 1 | Outcomes and costs associated with each strategy over 5 years: base case
Outcome variables No screen QA500 QA750
Proportion of patients who develop AVF thrombosis (%) 45.2 19.6 17.1
Proportion of patients who develop complete AVF failure owing to thrombosis (requiring temporary catheter) (%) 23.4 9.8 8.4
Mean number of months for which original AVF is used for dialysis 34.8 37.0 37.2
Proportion of patients dead by 5 years (%) 41.0 41.0 41.1
Proportion of patients transplanted by 5 years (%) 9.9 10.1 10.0
Proportion of patients who had an angiogram performed (%) 40.2 66.9 83.0
Mean number of angiograms per patient 0.40 1.27 1.55
Proportion of patients who had an angioplasty performed to treatment stenosis (%) 40.2 64.6 74.0
Mean number of angioplasties per patient 0.40 1.23 1.38
Mean number of catheter placements per patient over 5 years 0.679 0.251 0.229
Proportion of patients who ended up dialyzing with a permanent catheter (%) 14.5 5.3 4.9
Proportion of patients who end up dialyzing with an AVF created at a different location (%) 6.6 2.8 2.4
Proportion of patients who end dialyzing with a graft (%) 4.5 1.9 1.7
Access-related costs over 5 years (discounted at 5% in base case) $3910 $5130 $5250
Number needed to screen to prevent one AVF failure 7.4a 71b
Incremental cost to prevent one AVF failure $9030 $8520
Cost of screening $0 $1180 $1200
Cost of maintaining access patency $3300 $3770 $3880
i.e. angiograms, angioplasties, and declotting, temporary catheters
Cost of new access surgeries $610 $180 $170
AVF, arteriovenous fistulae.
aQA500 compared to No screen strategy.
bQA750 compared to QA500 strategy.
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angiography7) resulted in costs per fistula loss averted of
$10 150 and $25 530 for the QA500 (vs no screening) and
QA750 (vs QA500) strategies, respectively (Table 2).
Sensitivity analyses: likelihood of stenosis and AVF
thrombosis
Increasing the prevalence of stenosis or the risk of AVF
thrombosis improved the predicted cost effectiveness of both
screening strategies, compared with the base case (Table 2).
On the other hand, reducing the prevalence of stenosis or the
risk of thrombosis substantially decreased the economic
attractiveness of the QA750 strategy (compared with the
QA500 strategy) (Table 2).
Sensitivity analyses: availability and effectiveness of
angioplasty and declotting
The assumption that underlies the use of screening strategies
in AVF is that preemptive correction of stenosis with
angioplasty improves outcomes compared with an expectant
approach of declotting AVF after thrombosis. Therefore, both
screening strategies appeared more favorable in scenarios in
which angioplasty was more effective for preventing thrombo-
sis in stenotic but functioning AVF, when AVF declotting was
less effective than in the base case, or when facilities for AVF
declotting were unavailable (Table 2). In the base case analysis,
AVF that had undergone successful declotting were no longer
screened and their subsequent survival was based on the
available literature (Table 3).13–17 We reanalyzed the model
assuming that screening (and angioplasty, if required) was
continued after successful declotting, which did not substan-
tially alter our results (data not shown). Conversely, reducing
the efficacy of angioplasty for correction of stenosis, as might
be observed in clinical practice, reduced the economic
attractiveness of both screening strategies.
Sensitivity analyses: costs of screening procedure and health
care
Results were sensitive to the cost of the screening procedure.
As expected, increasing the cost of access screening by 50%
reduced the economic attractiveness of access screening. The
results of our analysis were not sensitive to plausible changes
in the estimates used for the cost of health care.
Sensitivity analyses: failure rate in AVF with stenosis but
Qa4500 ml/min
The base case analysis used data from a recent randomized
trial to estimate the risk of failure in AVF with Qa4500 ml/
min, despite untreated subclinical stenosis (11.3% per year).6
However, another recent publication indicates that the risk of
AVF loss in this situation is markedly lower.1 When this latter
scenario was modeled in sensitivity analysis, the economic
attractiveness of the QA500 strategy (compared with no
screening) remained unchanged, but the QA750 strategy
became considerably less attractive. Results were similar in an
intermediate scenario in which the risk of AVF loss in AVF
with untreated subclinical stenosis and Qa4500 ml/min was
5.7% per year. Thus, our findings were sensitive to the
prognosis of AVF with Qa between 500 and 750 ml/min.
Summary of findings from sensitivity analysis
In sensitivity analysis, the predicted net increase in costs from
screening 100 patients over 5 years ranged from as low as
$55 000 to as high as $180 300 for the QA500 strategy, and
from $69 000 to $192 500 for the QA750 strategy (each
compared with no screening). The results of the model were
not sensitive to plausible variations in the cost of health care,
rate of transplantation, overall risk of death, or discounting
rate. More detailed results of the sensitivity analyses appear in
the Supplementary Appendix.
Cost implications of AVF screening
There are approximately 280 000 hemodialysis patients in the
United States, of whom approximately 27–30% have AVF.
Our base case analysis suggests that the placement of
approximately 34 500 dialysis catheters could be averted,
and 11 400 cases of AVF failure prevented over 5 years if all
dialysis providers adopted the QA500 strategy, compared with
a scenario in which no screening was performed. However,
these clinical benefits would apparently require an additional
net outlay of approximately $100 million, representing an
average of $20 million annually.
DISCUSSION
This economic analysis used the best available data to project
the costs and consequences of two strategies for the screening
of AVF for stenosis, compared with no screening. The model
suggested that screening is associated with a modest net
increase in access-related costs, regardless of the Qa threshold
for angiography that is selected. In the base case scenario, the
mean increase in per-patient access-related costs associated
with screening was $1220 and $1340 over 5 years for the
QA500 and QA750 strategies, respectively. Thus, a hypothe-
tical dialysis unit with 100 patients with AVF that did not
perform screening could expect to spend an additional
$122 000 over 5 years to adopt the QA500 strategy, or
$134 000 to adopt the QA750 strategy.
We expressed the benefit associated with access screening
in terms of reductions in fistula loss and exposure to central
venous catheters. In the base case analysis, the model
predicted that 13.6 and 15% fewer patients would experience
fistula loss over 5 years in the QA500 and QA750 strategies,
and that 9.2 and 9.6% fewer patients would require a
permanent dialysis catheter over 5 years in the QA500 and
QA750 strategies. Although the monetary value of preventing
these outcomes is difficult to quantify, the absolute increases
in cost associated with screening were relatively modest,
suggesting that screening may represent good value for
money.
We performed a variety of sensitivity analyses to
determine which characteristics were likely to influence the
cost effectiveness of screening AVF for subclinical stenosis.
Both screening strategies appeared most economically
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Table 2 | Sensitivity analysis
Outcome variables No screening QA500 QA750
Base case analysis
Access-related costs over 5 years $3910 $5130 $5250
Number needed to screen to prevent one AVF failure 7.4 71
Incremental cost to prevent one AVF failure $9030a $8520
Screening strategies less sensitive and specific for stenosis7
Access-related costs over 5 years $3910 $5360 $5590
Number needed to screen to prevent one AVF failure 7 111
Incremental cost to prevent one AVF failure $10 150 $25 530
Prevalence of stenosis reduced to 0.3
Access-related costs over 5 years $3610 $4900 $5060
Number needed to screen to prevent one AVF failure 7.8 143
Incremental cost to prevent one AVF failure $10 080 $22 860
Prevalence of stenosis increased to 0.6
Access-related costs over 5 years $4190 $5330 $5430
Number needed to screen to prevent one AVF failure 6.3 52.6
Incremental cost to prevent one AVF failure $7170a $5260
Effectiveness of angioplasty at reducing AVF failure reduced by 50%
Access-related costs over 5 years $3910 $5276 $5424
Number needed to screen to prevent one AVF failure 8.9 111
Incremental cost to prevent one AVF failure $12 090 $16 440
Effectiveness of angioplasty at reducing AVF failure improved by 50%
Access-related costs over 5 years $3910 $4890 $5000
Number needed to screen to prevent one AVF failure 5.9 59
Incremental cost to prevent one AVF failure $5760 $6470
Risk of AVF failure reduced by 50% in all groups
Access-related costs over 5 years $3100 $4820 $4960
Number needed to screen to prevent one AVF failure 10.9 125
Incremental cost to prevent one AVF failure $18 700 $17 500
Risk of AVF failure increased by 50% in all groups
Access-related costs over 5 years $4390 $5350 $5470
Number needed to screen to prevent one AVF failure 6.4 55.6
Incremental cost to prevent one AVF failure $6110 $6670
AVF declotting not performed in any patients
Access-related costs over 5 years $4360 $5210 $5290
Number needed to screen to prevent one AVF failure 3.9 40
Incremental cost to prevent one AVF failure $3350a $3200
Probability of AVF declotting reduced to 0.5 (from 1.0) and efficacy of declotting reduced to 0.5 (from 0.89)
Access-related costs over 5 years $4310 $5,270 $5,370
Number needed to screen to prevent one AVF failure 4.6 4.3
Incremental cost to prevent one AVF failure $4420 $4560
AVF failure rate in patients with untreated stenosis with Qb4500 ml/min from observational data1
Access-related costs over 5 years $3860 $4950 $5120
Number needed to screen to prevent one AVF failure 6.6 250
Incremental cost to prevent one AVF failure $7220 $42 500
Mortality risks assumed different for patients with AVF, graft, line
Access-related costs over 5 years $3860 $5070 $5160
Number needed to screen to prevent one AVF failure 7.1 66.7
Incremental cost to prevent one AVF failure $8580a $6000
Cost of screening procedure increased by 50%
Access-related costs over 5 years $3910 $5713 $5835
Number needed to screen to prevent one AVF failure 7.4 71
Incremental cost to prevent one AVF failure $13 340a $8660
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attractive in scenarios where angioplasty of stenotic AVF was
assumed to be particularly effective for preventing thrombo-
sis, where stenosis was relatively frequent, or where declotting
of thrombosed AVF was unavailable or relatively ineffective.
As patency rates after AVF declotting appear to vary widely
between institutions,8,18 examination of local outcomes
following intervention in clotted AVF may aid dialysis
directors in deciding whether AVF screening would be
relatively advantageous for their facility.
In theory, dialysis units might perform access screening to
reduce costs, improve patient outcomes, or both. Previous
work found that vascular access screening reduces access-
related costs by decreasing the need for radiological
procedures and hospitalization.4 However, the majority of
subjects in this latter study had polytetrafluoroethylene
grafts, which thrombose and fail more frequently than AVF.
Our model captured all access-related costs (including
hospitalization for vascular procedures and sepsis) and found
no evidence that access screening reduced net costs under any
clinically plausible scenario. The slightly higher net access-
related costs associated with both screening strategies in AVF
suggest that Qa monitoring is worthwhile if reduced exposure
to central venous catheters translates into a morbidity or
mortality benefit – a hypothesis which (although unproven)
seems likely.11,19–21
Under the base case scenario, the incremental cost to
prevent an episode of AVF failure was similar for the QA500
and QA750 strategies, suggesting that if cost effectiveness
were the only consideration, an individual dialysis unit might
choose to adopt the QA750 strategy and prevent as many
Table 2 | Continued
Outcome variables No screening QA500 QA750
Cost of screening procedure decreased by 50%
Access-related costs over 5 years $3910 $4460 $4600
Number needed to screen to prevent one AVF failure 7.4 71
Incremental cost to prevent one AVF failure $4070 $9940
AVF, arteriovenous fistulae.
The QA500 strategy is compared with no screening, and the QA750 strategy is compared with the QA500 strategy.
aAlthough the QA500 strategy was more effective than the no screening strategy, it was associated with a higher incremental cost to prevent one AVF failure than the QA750
strategy (compared with the QA500 strategy), and as such, the QA500 is ruled out by extended dominance. In these cases, selection of the QA750 strategy provides more
clinical benefit per dollar spent, although more resources would be required per patient for the QA750 strategy, and in each instance, the absolute difference between the
QA500 and QA750 strategies is small.
Table 3 | Transition probabilities
Strategy
Variable No screen QA500 QA750 Sources
Prevalence of AVF stenosis 45% 45% 45% Tessitore et al.2
Sensitivity of transonic to detect stenosis NA 0.555 0.890 Tessitore et al.2
0.707 0.878 Schwarz et al.7
Specificity of transonic to detect stenosis NA 0.984 0.9 Tessitore et al.2
0.778 0.444 Schwarz et al.7
Likelihood of declot successa First declot 0.89 Haage et al.8
Second and subsequent declot 0
Risk of AVF failure after successful declot 3 mo: 0.25 Haage et al.8
6 mo: 0.35
12 mo: 0.5
After failure of initial AVF Manns et al.9
Probability of inserting perm. Catheter 0.336
Probability of creating second AVF 0.486
Probability of creating graft 0.178
After failure of second AVF
Probability of inserting perm. Catheter 0.562
Probability of creating second AVF 0.250
Probability of creating graft 0.188
Risk of primary access failure After creation of next AVF 0.47 Manns et al.9
After creation of graft 0.152
Annual risk of complete graft failure 0.30 Mehta et al.10
Yearly risk of death in patients with an AVF 0.105 Pasten et al.11
Yearly risk of transplant 0.027 Canadian Organ Replacement Register12
AVF, arteriovenous fistulae; mo, months.
aOnly one declot was attempted per AVF.
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episodes of AVF failure as possible. However, this conclusion
was sensitive to several assumptions, including the prevalence
of stenosis and the efficacy of angioplasty for preventing
thrombosis in stenotic AVF. Most importantly, if fistulae with
undetected stenosis but Qa4500 ml/min are unlikely to fail,1
the QA750 strategy does not represent an efficient use of
resources compared with the QA500 strategy. In the base case,
we derived the probability of AVF failure in this setting from
a study in which follow-up Qa measurements did not trigger
angiography, even if Qa declined further over time.6
Although an AVF with stenosis and an initial Qa of 600 ml/
min would not initially undergo angiography under the
QA500 strategy, the available data suggest that in most such
cases, Qa will decline to o500 ml/min on follow-up
measurements – allowing the lesion to be detected and
treated before thrombosis occurs. Thus, the base case
probably underestimates the cost to prevent an episode of
AVF loss associated with the QA750 strategy, especially when
follow-up Qa measurements are regularly performed. Finally,
the number of angiograms required under the QA750 strategy
was approximately 22% higher than in the QA500 strategy,
which may be an additional consideration in settings where
access to angiography is limited.
Our analysis took a single-payor perspective, which
appears appropriate for the United States as well as Canada,
as Medicare in the United States reimburses both access
screening (via the composite rate for outpatient dialysis) and
hospitals for providing angiograms and access surgery.
However, there appears to be little financial incentive for
dialysis providers to screen AVF for subclinical stenosis, as
reimbursement for dialysis does not appear to be contingent
on the performance of access screening. At present, there is
no consensus as to whether $9,000 represents a reasonable
expenditure to prevent one episode of AVF failure. If such
consensus is reached, linking reimbursement to the actual
provision of access screening in AVF could be considered.
Our study has several limitations that should be
considered. First, there was considerable uncertainty in some
of the model parameters. We attempted to deal with this
through extensive use of sensitivity analysis and found that
screening AVF for subclinical stenosis was not cost saving
under any plausible scenario. Although it is possible that the
QA750 strategy is marginally more cost effective than the
QA500 strategy, the incremental cost for the two strategies
varied from similar (under most scenarios) to substantially
higher for the QA750 strategy. We did not find the QA750
strategy to be substantially more cost effective than the
QA500 strategy under any scenario. Second, although costs
were predominantly based on Canadian data, using data that
reflected higher health-care costs (as in the US) did not
qualitatively alter our conclusions. In addition, clinical data
were derived from Canadian, Italian, and German studies. As
such, our results are likely applicable to other health-care
settings. However, the use of multiple different studies to
estimate the causes and consequences of screening may have
introduced additional uncertainty which was not captured by
our model. Third, as many centers do not perform declotting
of native AVF, screening may be more beneficial than our
base case analysis suggests. Fourth, we did not consider other
potential screening strategies such as regular physical
examination, less frequent Qa measurements, or lower QA
thresholds. Although potentially less expensive than the
screening strategies we evaluated, the effectiveness of these
strategies is unclear. Fifth, we did not have data on health-
related quality of life, which might well be affected by access
failure and also by strategies aimed at preventing it. Sixth, we
assumed that nurses (rather than dialysis technicians) would
perform access screening, which reflects clinical practice in
Canada. Using less costly personnel to perform Qa measure-
ments would be expected to improve the cost effectiveness of
both screening strategies, although, as noted within our
sensitivity analysis, it did not make screening cost saving.
Finally, decision models may not sufficiently capture
complexities of clinical decision making. However, as
suggested by modeling guidelines,22 we have attempted to
create a model which is as simple as possible while capturing
the essentials of health states and interventions. It is
reassuring that the incidence of AVF failure, as predicted by
the model, was similar to that observed in the control arm of
a prospective clinical trial.6 Our conclusions may require
modification as new evidence emerges, as the number of
patients with AVF failure in the available clinical trials was
low. In addition, a more precise estimate of the risk and
consequences of AVF failure would have been useful for our
analysis. Finally, future studies should confirm the prognosis
of apparently well-functioning AVF with Qa4500 ml/min, as
this variable was of critical importance for our analysis.
In conclusion, screening AVF for subclinical stenosis does
not appear to reduce access-related costs, although the
modest predicted cost of $8000–$10 000 to prevent one
episode of AVF failure may represent good value for money.
The incremental cost effectiveness of screening was similar in
the base case for the QA500 and QA750 strategies. However,
adopting the QA750 strategy would require a relatively large
number of additional angiograms to prevent an episode of
AVF failure, and the relative economic attractiveness of this
strategy (compared with the QA500 strategy) was adversely
affected under several plausible scenarios. These data suggest
that dialysis providers which perform access screening in AVF
should use the QA500 strategy, especially in settings where
access to angiography is limited.
MATERIALS AND METHODS
Population
In the baseline analysis, we evaluated a simulated cohort of prevalent
hemodialysis patients whose characteristics were representative of
typical North American dialysis patients with AVF in terms of age
(38% were over 60 years of age), sex (68% male), and comorbidity
(23% with diabetes).11 To be consistent with the best quality study
on this topic,2 in the base case analysis, we assumed the prevalence
of stenosis in functioning AVF to be 45%.2 We considered the
impact of higher7 and lower estimates in sensitivity analyses.
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Screening strategies
We assumed that screening studies would be performed bimonthly
using indicator dilution technology, where the ultrasound velocity
through blood is the indicator, and dilution is provided by a bolus
of normal.7,23 For purposes of resource use, we assumed that
patients would have Qa measured twice in succession during the
same dialysis treatment, and that a Transonic HD02 device
(Transonic Systems Inc., Ithaca, NY, USA) would be used for
screening. In all scenarios, we assumed that AVF with clinical
evidence of dysfunction or abnormalities on physical examination
would undergo angiography.
Model
We used decision analysis to model the costs and consequences of
different Qa thresholds for angiography in patients with native
vessel AVF over a 5-year period. The perspective of the economic
evaluation was that of the health-care purchaser as only direct health
service costs were analyzed. A Markov process24 was used to model
transitions, over recurring 2-month cycles, between the different
clinical states that were considered (see Figure 1 and Supplementary
Appendix). As the impact of AVF failure on patients’ survival and
health-related quality of life is unknown, expressing the results as a
cost per quality-adjusted life year would be inappropriate. There-
fore, the potential clinical benefit of screening was expressed as the
expected number of months that each patient could be dialyzed with
an AVF (rather than a dialysis catheter or graft), the occurrence of
AVF failure (abandonment of the AVF for use in dialysis), and the
number of dialysis catheter insertions and other access-related
procedures that would be required per patient.
Diagnostic properties of access flow monitoring and efficacy
of treatment for stenosis
Two prospective studies in AVF have performed both Qa monitoring
and angiography in all subjects (regardless of Qa).2,7 These data were
used to construct receiver operating characteristic curves for the
diagnostic efficiency of different Qa thresholds to detect hemodyna-
mically significant stenosis. In the base case analysis, we used the
data from Tessitore et al.;2 sensitivity analyses considered results
from the study by Schwarz et al.7 The efficacy of angioplasty for
correcting stenosis was estimated as specified in the Supplementary
Appendix.6,28 We obtained the other necessary clinical parameters
from a literature review (Table 3).
Resource use
All costs are measured in 2002 Canadian dollars (1 CAN$
¼ 0.69US$) (Table 3). Screening costs were estimated from a
Canadian prospective study of hospital-based outpatient hemodia-
lysis clinics, and were based on the annual number of access-
screening procedures, the useful life of the screening device
(7 years), and the nursing time required for monitoring.9 This
included nursing time for arranging angiograms that were ordered
because of screening, and organizing any subsequent management
(angioplasty and surgery). The cost of other access-related
healthcare included costs from all access-related procedures,
hospitalization for access-related indications, and treatment of
outpatient access-related infections9 (Table 4). The cost of caring for
patients who did not receive screening included these latter access-
related costs, but not costs due to screening. We did not consider
health-care costs that were unrelated to vascular access as they are
not known to be influenced by access screening.
Sensitivity analysis
As any model involves assumptions and uncertainties, extensive
sensitivity analyses were carried out. These analyses assessed the
effect of varying baseline estimates within clinically plausible ranges
on access-related costs and clinical outcomes including the
probability of AVF failure, and the number of angiograms and line
placements required (Supplementary Appendix).
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Figure 1 | Flow diagram for decision tree.
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Table 4 | Cost of vascular access screening and procedures
Variable Base case Range Sources
Cost of ultrasound screening per session $58 Manns et al.9
Cost of fistulogram without angioplasty $484 Manns et al.9
Cost of fistulogram and angioplasty $1172 Manns et al.9
Cost of AVF declot $1203 Manns et al.9
Cost of surgery to create a new AVF $1558 Manns et al.9
Cost of surgery to create a new graft $1780 Manns et al.9
Cost of inserting a temporary dialysis line $601 Manns et al.9
Cost of inserting a permanent dialysis line $925 Manns et al.9
Mean cost of maintaining a functioning AVF per yeara $586 $0–732 (interquartile range) Lee et al.25
Mean cost of maintaining a graft per yearb $4850 $590–6725 (interquartile range) Lee et al.25
Mean cost of maintaining a permanent dialysis catheter
per yearc
$3238 $0–3156 (interquartile range) Lee et al.25
Discount rate (costs and effects) 5% per annum Canadian Coordinating Office
for Health Technology Assessment26
AVF, arteriovenous fistulae.
aIncludes cost of maintaining AVF per year (including cost of fistulograms done for clinical indications and not related to ultrasound screening technique).
bCost of maintaining a graft per year (including cost of fistulograms, angioplasties and cost of new access surgeries required).
cCost of maintaining a permanent dialysis catheter (including cost of new catheters required for malfunction, costs of TPA, and cost of treating infections (including
hospitalization)).
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